There are PED's in nexxus, only the location in the eye of the PED is controlled "no PED's in this certain location" is the way it's worded.
They didn't restart it as a separate trial to save money.
Further study details as provided by Lpath, Inc.:
Primary Outcome Measures:
•Progression-Free Survival [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
The study will use a two-cohort design based on an 8-week PFS rate. Treatment will be considered promising if at least 12 out of the first 22 eligible subjects entered in the Cohort 1 of the study are progression free at Week 8. Enrollment of Cohort 2 will then proceed and be considered worthy of further evaluation if at least 25 out of 39 eligible subjects are progression free at Week 8. If no efficacy signal is observed after enrollment of 22 subjects in Cohort 1, the second cohort will not be enrolled and the clinical study may be stopped.
So if in a few months they should be able to announce the # and % of progrression free subjects? No double blinding here.
So they are a year behind schedule? Maybe that explains why the price is so cheap. I wonder what it will be when they get those things done? As far as "partnering Lpathomab" I think they want to get bought out for it instead, might not be great to partner Lpathomab, except through DOD, which is more in line with what they have said this year and last year.
Tried to reply to John but it won't let me for some reason.
Western States Investment Corp is run by Donald Swortwood and Letitia Swortwood. They helped start Lpath and each of them has a lot of stock in Lpath.
If you look at the Western States website they list Lpath as one of the companies in their portfolio.
Telling Merk to take a hike, and then making them pay a milestone was not a bad move, unless you think they really had a better deal, and are a better company than Pfizer.
Is Asonep a open trial? They say on clinical trials dot gov if the first 8 weeks shows no improvement they can bail and stop the trial. If that's the case, then continueing it will be a good sign.
Also, if Pfizer opts in, I don't care if they publish results or not, opting in is the thing.
No new drugs, no new trials, didn't he say they hoped to have two deals to produce antibodies this year? One in a couple months, one later?
I would like to see them do their own PED trial, that would be a ballsy move, and they said Pfizer has no problem with them doing it, Pfizer just doesn't want to pay for a second trial, they never did want to because they don't see PED's as a big deal.
Besides that, I agree the down turn is directly related to the last offering, the trial delay and the cancelling of the PED trial.
It's not really new news, since they said at the conference call the same thing, but it could be big depending on the target. They have discussed a celebrex type pain killer as a potential drug if someone wanted to partner up on it, anyone know of any other widely discussed lipid targets?
Also, anybody figure out the "Biogen IDec" connection to Lpath that was mentioned? I can't find anything about it in the past, searching the web.
I've never seen a conference like that, surfing lessons, Bicycling with Bill Walton, (I guess he's sick of Basketball) , at the Ritz Carlton, pretty swanky.
Just log in as your "pancoast421" alias, and you can have an imaginary conversation with him, I'm putting you back on ignore like most everyone else here seems to have done.
In phase 1 testing one PED went away for a year at least I think.
One got a lot better. Neither had responded to Lucentis or Avastin from what I remember.
If the drug is approved for wet AMD it will probably be tried off label for PED's, but I think there are PED's in the Wet AMD trial so we may know more later about that.
I heard J&J was involved in the past, what's with Biogen Idec? Have they been involved before?
They seem like a company that would be interested in Lpathomab, maybe for MS.
Lpath, Inc. ( NASDAQ : LPTN ), the industry leader in bioactive lipid-targeted therapeutics, has been invited to present at the ROTH Capital Partners 25th Annual Growth Stock Conference being held on March 17-20, 2013, at The Ritz Carlton in Dana Point, Calif.
Lpath President and CEO Scott Pancoast is scheduled to present on Tuesday, March 19, 2013 at 1:00 p.m. Pacific time, with one-on-one meetings held throughout the day. He will discuss the company's pathway to regulatory approval and commercialization of its novel lipidomics-based therapeutics, as well as its ability to attract support from financial and strategic partners such as Pfizer, J&J, Biogen Idec, and Merck-Serono, as well as the NIH and the Department of Defense.
The presentation will be webcast live
Maybe it will work like this, a ambulance is called because a guy is laying on the side walk. He's breathing but unconcious. Paramedics check him and see a slight bump on his head, but don't know what is wrong with him. They give him some test, the TBI drop of blood test shows high LPA levels. They give him LPathomab, and later his brain doesn't look like rat A from the Lpath presentation, it looks like rat B instead. Lpathomab saves the day.
If you look up the different recent articles about this you will see the DOD gave a company 7 million dollars to try to come up with a brain wave reader to diagnose TBI in 2007 i believe, and other companies are trying to make similar things. They might use this in the battle field, football, rugby, soccer etc fields. One story mentioned some player that was cleared to play weeks after getting his clock cleaned and then had to be taken out after a few minutes of playing because he started showing signs of a concussion, when everybody thought he was fine.
AMERICAN researchers are developing a hand-held blood diagnostic machine that will allow medical staff to assess within minutes whether an athlete has suffered concussion or a sub-concussive injury
A prototype of the machine, which requires a pin#$%$ of blood, has been produced in the US but will not be available or approved until clinical tests are completed over the new few years.
Professor Roger Sabbadini said the machine, which would be similar to a glucose-testing kit for diabetics, could also be used in conjunction with a urine test.
"The idea is that if you can diagnose those things on the sidelines at a game, such as Aussie Rules ... you can intervene and do something about it and mitigate it," Sabbadini said last night. "What we are doing is a rapid point-of-care diagnostic."
Researchers have discovered a brain-damage marker in the bloodstream that will help doctors diagnose and treat concussion.
Elevated protein levels in the bloodstream can reveal whether a player has suffered concussions.
Sabbadini said the biomarker - cerebrospinal fluid - was present in the brain of traumatic brain injury patients.
He said the testing could also be used on road accident victims and military people subjected to bomb blasts in the battlefield.
"We are developing a diagnostic for early detection of traumatic brain injury.
"The diagnostic test is based on an ANTIBODY, which has been developed in the laboratory.
"The antibody isn't only the basis for detecting the analysed biomarker, but is also a potential therapeutic.
"The dream is to have a pairing between a diagnostic and therapeutic."
Sabbadini said the testing would help club medical staff operating on the sidelines to make a decision regarding whether the player was injured and if he should go back on to the field or needed urgent medical treatment.
Yes, I bet institutional ownership will be up next quarter , they don't mind waiting a year unlike some.
I count 19 % like Google says on Whale wisdom, with 143% increase according to them. That doesn't count Ailsa Craig Trust or Peierls Foundation. Peirels had 10 % in 2011. Anybody know Bou Juan Carlos 8 percent owner in 2011? (insider cow)
Baker Bros and those other institutions didn't buy shares to short them, this is the impatient people getting out. Good luck and happy accumulating.
Sentiment: Strong Buy